文献速递头颈与中枢神经肿瘤

基因组改变与治疗暴露塑造胶质母细胞瘤复发的时空模式

Genomic alterations and treatment define spatiotemporal patterns of glioblastoma recurrence.
PubMed 文献 · Cancer Discov · 2026-10-01

该研究对40例胶质母细胞瘤患者的手术切缘及邻近复发肿瘤区域进行组织学引导采样和单细胞空间转录组分析,并与配对原发肿瘤比较。手术切缘在治疗后呈现独特的创愈微环境,富集间质样恶性状态并定义「基质」亚型。复发时转为该亚型的患者具有早期TP53突变、替莫唑胺辅助治疗期间持续增殖和较短生存;TP53野生型肿瘤在替莫唑胺治疗期间复发则向间质亚型转变,p53通路活性增加且增殖减少。

要点

  • 手术切缘是胶质母细胞瘤复发主要部位,具有独特创愈微环境和间质样恶性状态。
  • 复发时转为「基质」亚型者与早期TP53突变、替莫唑胺治疗期间持续增殖及较短生存相关。
  • TP53野生型肿瘤在替莫唑胺治疗中复发向间质亚型转变,p53通路活性升高且增殖降低。

核心结论

  • 胶质母细胞瘤复发轨迹与基因组背景、治疗暴露和临床结局相关,手术切缘的分子特征定义了不同复发模式。

研究设计与样本

  • 对40例患者的原发肿瘤、手术切缘及邻近复发肿瘤区域进行组织学引导采样和单细胞空间转录组分析。

主要发现

  • 手术切缘在治疗后构成独特的创愈微环境。
  • 手术切缘富集具有显著间质转录组和组织学特征的恶性状态,并定义「基质」亚型。
  • 复发时转为「基质」亚型的患者具有早期TP53突变、替莫唑胺辅助治疗期间持续增殖和较短生存。
  • TP53野生型肿瘤在替莫唑胺治疗期间复发向间质亚型转变,伴p53通路活性增加和增殖减少。
  • 在患者来源胶质母细胞瘤模型中,TP53功能缺失增加替莫唑胺耐药。

临床怎么用

  • 关注手术切缘的分子特征可能有助于识别胶质母细胞瘤复发轨迹和预后分层。
  • TP53突变状态和替莫唑胺治疗暴露可提示复发时间质亚型转变风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The surgical margin is the primary site of glioblastoma recurrence, yet its molecular features remain poorly characterized. We performed histology-guided sampling and single-cell spatial transcriptomics of surgical margin and adjacent recurrent tumor regions, with matched primary tumors from 40 patients. The surgical margin constituted a distinct wound-healing microenvironment in the post-treatment setting. We also identified malignant states with pronounced mesenchymal transcriptomic and histological features that were enriched at the surgical margin and defined a "stromal" subtype. Patients who transitioned to this subtype at recurrence were characterized by early TP53 mutation, sustained proliferation during adjuvant temozolomide treatment, and shorter survival. Conversely, patients with TP53-wild-type tumors recurring during temozolomide treatment transitioned toward the mesenchymal subtype, with increased p53 pathway activity and reduced proliferation. Functional validation showed TP53 loss-of-function increased temozolomide resistance in a patient-derived glioblastoma model. Our findings identify distinct glioblastoma recurrence trajectories linked to genomic context, treatment exposure, and clinical outcomes.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Artzi SB, Harwood DSL, Locallo A, et al. Genomic alterations and treatment define spatiotemporal patterns of glioblastoma recurrence. Cancer Discov. 2026. PMID: 42820945. doi:10.1158/2159-8290.CD-25-2302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。